Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Gastrinoma 2Adenoma, Islet Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Neoplasm Metastasis 1Insulinoma 1Glucagonoma 1Carcinoma, Islet Cell 1

Interventions

Trastuzumab 2tipifarnib 1temsirolimus 1romidepsin 1antineoplaston AS 2-1 1antineoplaston A10 1Streptozocin 1Sorafenib 1Sirolimus 1Oxaliplatin 1Melphalan 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Gefitinib 1Floxuridine 1Complementary Therapies 1Cisplatin 1Capecitabine 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Islet Cell × Streptozocin × Clear all
NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡